|
|
Graves病抗甲状腺药物治疗停药后复发的相关因素
|
Abstract:
Graves病的治疗方法多种，其中以抗甲状腺药物治疗为主，一般疗程12~18个月。最近半年小剂量抗甲状腺药物治疗下甲功正常、TRAb阴性一般可以停药，但停药后复发率高。准确掌握停药指针对于降低复发十分重要。研究表明停药时甲状腺体积大、ATD疗程短、偏高的TRAb水平、偏低TSH的水平、较快的甲状腺上动脉血流速度、较高的T3/fT4比值、较高的碘摄入、高NRL及低TPOAb和TgAb滴度等与停药后复发相关。因此在停用ATD之前，应该关注上述指标，避免不恰当停药导致复发。
There are many treatments for Graves’ disease, among which antithyroid drugs are the main treatment, and the general course of treatment is 12~18 months. In the last six months, patients with normal thyroid function and negative TRAb can generally stop taking antithyroid drugs, but the recurrence rate is high after stopping taking them. It is very important to master the withdrawal indicator accurately to reduce recurrence. Studies have shown that the recurrence after drug withdrawal is related to large thyroid volume, short ATD course, high TRAb level, low TSH level, fast blood flow velocity of superior thyroid artery, high T3/fT4 ratio, high iodine intake, high NRL and low TPOAb and TgAb titers. Therefore, before stopping ATD, we should pay attention to the above indicators to avoid the recurrence caused by improper withdrawal.
| [1] | 徐海龄, 冉建民, 劳干诚, 等. Graves病并甲亢药物治疗停药后复发相关临床因素分析[C]//中华医学会第十二次全国内分泌学学术会议论文集. 2013: 268-269. |
| [2] | 周爱新. 药物治疗后甲状腺功能亢进症患者复发因素分析——287例报告[J]. 新医学, 1999, 30(10): 581-582. |
| [3] | 柳林, 卢洪文, 刘长山, 刘阳. 抗甲状腺药物治疗格雷夫斯病复发情况及相关因素分析[J]. 中华全科医师杂志, 2016, 11(6): 437-440. |
| [4] | Laurberg, P., Krejbjerg, A. and Andersen, S.L. (2014) Relapse Following Antithyroid Drug Therapy for Graves’ Hyperthyroidism. Current Opinion in Endocrinology, Diabetes & Obesity, 21, 415-421. https://doi.org/10.1097/med.0000000000000088 |
| [5] | 王玉英, 桑淑英. 格雷夫斯病药物治疗探讨[J]. 现代中西医结合杂志, 2004, 13(6): 729-730. |
| [6] | 沈屹, 杨莉. 小剂量抗甲状腺药物缓解毒性弥漫性甲状腺肿的临床意义[J]. 中国乡村杂志, 2012, 19(3): 14-15. |
| [7] | Bahn, R.S., Burch, H.B., Cooper, D.S., Garber, J.R., Greenlee, M.C., Klein, I., et al. (2011) Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid, 21, 593-646. https://doi.org/10.1089/thy.2010.0417 |
| [8] | 张晓丽, 刘馨悦, 刘波. TRAb的动态监测在Graves 病中的临床意义[J]. 中国实验诊断学, 2016, 20(4): 651-653. |
| [9] | Laurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G. and Tørring, O. (2008) Tsh-Receptor Autoimmunity in Graves’ Disease after Therapy with Anti-Thyroid Drugs, Surgery, or Radioiodine: A 5-Year Prospective Randomized Study. European Journal of Endocrinology, 158, 69-75. https://doi.org/10.1530/eje-07-0450 |
| [10] | 孙爽. 甲亢患者妊娠早期停药后复发的相关因素分析及对妊娠结局的影响[D]: [硕士学位论文]. 沈阳: 中国医科大学, 2018. |
| [11] | 王少波, 周善存, 梁志丽. Hs-TSH维持水平与ATD治疗Graves病甲亢预后的关系[J]. 国际医药卫生导报, 2011, 17(3): 281-283. |
| [12] | 张勤, 池莲祥, 周波, 徐华. ATD治疗Graves病甲亢的预后与血清TSH关系的研究[J]. 华西医学, 2006, 21(3): 450-451. |
| [13] | Laurberg, P., Krejbjerg, A. and Andersen, S.L. (2014) Relapse Following Antithyroid Drug Therapy for Graves’ Hyperthyroidism. Current Opinion in Endocrinology, Diabetes & Obesity, 21, 415-421. https://doi.org/10.1097/med.0000000000000088 |
| [14] | Orgiazzi, J. and Madec, A. (2002) Reduction of the Risk of Relapse after Withdrawal of Medical Therapy for Graves’ Disease. Thyroid, 12, 849-853. https://doi.org/10.1089/105072502761016467 |
| [15] | Takamatsu, J., Sugawara, M., Kuma, K., Kobayashi, A., Matsuzuka, F., Mozai, T., et al. (1984) Ratio of Serum Triiodothyronine to Thyroxine and the Prognosis of Triiodothyronine-Predominant Graves’ Disease. Annals of Internal Medicine, 100, 372-375. https://doi.org/10.7326/0003-4819-100-3-372 |
| [16] | Park, S., Song, E., Oh, H., Kim, M., Jeon, M.J., Kim, W.G., et al. (2019) When Should Antithyroid Drug Therapy to Reduce the Relapse Rate of Hyperthyroidism in Graves’ Disease Be Discontinued? Endocrine, 65, 348-356. https://doi.org/10.1007/s12020-019-01987-w |
| [17] | 中华医学会内分泌学分会. 中国甲状腺疾病诊治指南——甲状腺功能亢进症[J]. 中华内科杂志, 2007, 46(10): 876-882. |
| [18] | 吴欣, 宋兆杰, 王时宏, 等. 彩超对药物治疗后甲亢复发患者甲状腺上动脉血流的研究[J]. 临床军医杂志, 2013(3): 315-316. |
| [19] | 刘光清, 黄利, 郑海龙, 梁娴, 赵妍妍. 甲状腺上动脉血流速度改变对药物治疗甲亢复发的预测价值[J]. 海南医学院学报, 2018, 24(5): 647-650. |
| [20] | Roti, E. (1993) Effects of Chronic Iodine Administration on Thyroid Status in Euthyroid Subjects Previously Treated with Antithyroid Drugs for Graves’ Hyperthyroidism. Journal of Clinical Endocrinology & Metabolism, 76, 928-932. https://doi.org/10.1210/jc.76.4.928 |
| [21] | Laurberg, P., Krejbjerg, A. and Andersen, S.L. (2014) Relapse Following Antithyroid Drug Therapy for Graves’ Hyperthyroidism. Current Opinion in Endocrinology, Diabetes & Obesity, 21, 415-421. https://doi.org/10.1097/med.0000000000000088 |
| [22] | Solomon, B.L., Evaul, J.E., Burman, K.D. and Wartofsky, L. (1987) Remission Rates with Antithyroid Drug Therapy: Continuing Influence of Iodine Intake? Annals of Internal Medicine, 107, 510-512. https://doi.org/10.7326/0003-4819-107-4-510 |
| [23] | Kim, M., Kim, B.H., Jang, M.H., Kim, J.M., Kim, E.H., Jeon, Y.K., et al. (2019) High Neutrophil-to-Lymphocyte Ratio Is Associated with Relapse in Graves’ Disease after Antithyroid Drug Therapy. Endocrine, 67, 406-411. https://doi.org/10.1007/s12020-019-02137-y |
| [24] | 颜闪闪, 刘小玉, 刘长山. 格雷夫斯病药物治疗效果影响因素分析[J]. 社区医学杂志, 2020, 18(5): 328-331+335. |
| [25] | 任丽萍, 卢泽芬, 何庆, 等. 血清甲状腺过氧化物酶抗体对Graves病合并桥本甲状腺炎的诊断意义[J]. 天津医药, 2016, 44(11): 1305-1307+1409. |
| [26] | Choi, Y.M., Kwak, M.K., Hong, S.M. and Hong, E. (2019) Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves’ Disease Relapse after Antithyroid Drug Therapy. Endocrinology and Metabolism, 34, 268-274. https://doi.org/10.3803/enm.2019.34.3.268 |
| [27] | Schott, M., Eckstein, A., Willenberg, H., Nguyen, T., Morgenthaler, N. and Scherbaum, W. (2007) Improved Prediction of Relapse of Graves’ Thyrotoxicosis by Combined Determination of TSH Receptor and Thyroperoxidase Antibodies. Hormone and Metabolic Research, 39, 56-61. https://doi.org/10.1055/s-2007-957347 |
| [28] | 宋巍巍. 长期使用甲疏咪唑治疗甲亢的临床疗效和安全性分析[J]. 吉林医学, 2016, 37(9): 2230-2231. |
